Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
16.45
-0.26 (-1.56%)
At close: Feb 10, 2026, 4:00 PM EST
16.53
+0.08 (0.49%)
After-hours: Feb 10, 2026, 4:29 PM EST
Nurix Therapeutics Employees
Nurix Therapeutics had 317 employees as of November 30, 2025. The number of employees increased by 31 or 10.84% compared to the previous year.
Employees
317
Change (1Y)
31
Growth (1Y)
10.84%
Revenue / Employee
$264,921
Profits / Employee
-$834,249
Market Cap
1.69B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Nov 30, 2025 | 317 | 31 | 10.84% |
| Nov 30, 2024 | 286 | 2 | 0.70% |
| Nov 30, 2023 | 284 | -13 | -4.38% |
| Nov 30, 2022 | 297 | 55 | 22.73% |
| Nov 30, 2021 | 242 | 107 | 79.26% |
| Nov 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 407 |
| Ardelyx | 395 |
| Zymeworks | 263 |
| Tango Therapeutics | 155 |
| Pharvaris | 118 |
| Definium Therapeutics | 74 |
| Enliven Therapeutics | 65 |
| RAPT Therapeutics | 60 |
NRIX News
- 13 days ago - Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 25 days ago - Nurix Therapeutics: Why This Company Could Double In Value? - Seeking Alpha
- 4 weeks ago - Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside - Seeking Alpha
- 4 weeks ago - Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript - Seeking Alpha
- 2 months ago - Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - GlobeNewsWire